Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HIV-1 Infection in Adults”

388 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 388 results

Early research (Phase 1)Study completedNCT00428337
What this trial is testing

Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 36
Testing effectiveness (Phase 2)Study completedNCT01734850
What this trial is testing

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

Who this might be right for
Human Immunodeficiency Virus
Calimmune, Inc. 13
Large-scale testing (Phase 3)Study completedNCT01968551
What this trial is testing

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

Who this might be right for
HIV-1HIV InfectionsAcquired Immunodeficiency Syndrome
Gilead Sciences 158
Large-scale testing (Phase 3)Study completedNCT02605954
What this trial is testing

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

Who this might be right for
HIV-1 Infection
Gilead Sciences 275
Not applicableStudy completedNCT05634265
What this trial is testing

Social Media for ART Adherence and Retention in Adolescents and Young Adults: the Vijana-SMART Study

Who this might be right for
HIV-1-infectionAdherence, MedicationDepression
University of Washington 55
Testing effectiveness (Phase 2)Ended earlyNCT04493216
What this trial is testing

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

Who this might be right for
HIV Infections
ViiV Healthcare 161
Post-approval studies (Phase 4)Study completedNCT03797014
What this trial is testing

B/F/TAF Switch Study for HIV-HBV Coinfection

Who this might be right for
HIV-1-infectionHepatitis B
University of Maryland, Baltimore 28
Early research (Phase 1)Study completedNCT04799353
What this trial is testing

Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)

Who this might be right for
Human Immunodeficiency Virus (HIV)
AbbVie 33
Early research (Phase 1)Study completedNCT00004579
What this trial is testing

See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

Who this might be right for
HIV InfectionsHIV Seronegativity
Walter Reed Army Institute of Research (WRAIR)
Testing effectiveness (Phase 2)Study completedNCT02369146
What this trial is testing

To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults

Who this might be right for
HIV-1 Infection
United BioPharma 29
Large-scale testing (Phase 3)Study completedNCT01227824
What this trial is testing

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

Who this might be right for
Infection, Human Immunodeficiency Virus I
ViiV Healthcare 828
Large-scale testing (Phase 3)Study completedNCT03446573
What this trial is testing

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

Who this might be right for
HIV Infections
ViiV Healthcare 743
Early research (Phase 1)Study completedNCT01095224
What this trial is testing

Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 180
Large-scale testing (Phase 3)Study completedNCT00450580
What this trial is testing

HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults

Who this might be right for
Infection, Human Immunodeficiency Virus IHIV-1 Infection
ViiV Healthcare 212
Large-scale testing (Phase 3)Study completedNCT01440569
What this trial is testing

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Who this might be right for
Acquired Immunodeficiency SyndromeHIV Infections
Gilead Sciences 314
Early research (Phase 1)Study completedNCT04223804
What this trial is testing

Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

Who this might be right for
Human Immunodeficiency Virus (HIV)HIV InfectionHIV-1
AbbVie 41
Large-scale testing (Phase 3)Study completedNCT01939197
What this trial is testing

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection

Who this might be right for
Hepatitis C Virus InfectionHuman Immunodeficiency Virus InfectionChronic Hepatitis C+1 more
AbbVie 318
Early research (Phase 1)Study completedNCT00089531
What this trial is testing

Candidate HIV Vaccine

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 15
Early research (Phase 1)WithdrawnNCT03505060
What this trial is testing

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID)
Post-approval studies (Phase 4)Study completedNCT00055120
What this trial is testing

When to Start Anti-HIV Drugs in Patients With Opportunistic Infections

Who this might be right for
HIV InfectionsAIDS-Related Opportunistic Infections
National Institute of Allergy and Infectious Diseases (NIAID) 283
Next Page